Avenue Therapeutics amends bylaws, removes InvaGen special rights, changes quorum

AVENUE THERAPEUTICS, INC.

Board adopted Second Amended and Restated Bylaws effective February 9, 2023.
Removed all special rights and provisions previously granted to InvaGen Pharmaceuticals Inc.
Quorum for stockholder meetings changed to majority of outstanding voting power.
No immediate financial or operational impact disclosed.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

AVENUE THERAPEUTICS, INC.: Removed special rights provisions for InvaGen Pharmaceuticals and changed stockholder meeting quorum requirement to majority of outstanding voting power (effective 2023-02-09).

Change: bylaw amendment
Effective: 2023-02-09

Exact text from the filing

On February 9, 2023, the Board of Directors (the “Board”) of Avenue Therapeutics, Inc. (the “Company”) adopted the Second Amended and Restated Bylaws of the Company (the “Amended Bylaws”), effective immediately.

View on SEC.gov

Browse all governance changes →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-018503

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.